Accel Wealth Management Recursion Pharmaceuticals, Inc. Transaction History
Accel Wealth Management
- $257 Million
- Q4 2024
A detailed history of Accel Wealth Management transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Accel Wealth Management holds 45,800 shares of RXRX stock, worth $299,074. This represents 0.12% of its overall portfolio holdings.
Number of Shares
45,800Holding current value
$299,074% of portfolio
0.12%Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
289Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$214 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$165 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$159 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$113 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$100 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.18B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...